CysLT1 receptor upregulation by TGF-beta and IL-13, but not IL-4, is associated with bronchial smooth muscle cell proliferation in response to LTD4

Abstract Background: Airway remodeling is a feature of chronic asthma. It involves a number of structural changes, including bronchial smooth muscle cell (BSMC) hyperplasia and hypertrophy. Cysteinyl leukotrienes (cysLTs) have been suggested to play a role in airway remodeling in addition to their numerous other physiopathologic effects. Objectives: This work was aimed at characterizing the potential modulation of CysLT1 receptor expression by cytokines and the eventual functional relevance of this modulation. Methods: Expression of CysLT1 receptor was measured by flow cytometry and immunofluorescence microscopy. Transcripts were measured by RT-PCR and BSMC proliferation by crystal violet staining. Results: When human BSMC were exposed to transforming growth factor (TGF)-β, IL-13, or IFN-γ, their expression of CysLT1 receptor was significantly augmented in a time- and concentration-dependent manner. Interestingly, IL-4 had no significant effect on CysLT1 receptor expression in BSMC. Moreover, IL-13 and IFN-γ but not TGF-β were able to increase CysLT1 mRNA levels. Finally, when BSMC were pretreated with TGF-β or IL-13 but not IFN-γ, their responsiveness to LTD 4 was markedly enhanced in terms of BSMC proliferation. Whereas TGF-β, IL-13, or LTD 4 alone had little effect on BSMC proliferation, preexposure of the cells to TGF-β or IL-13 for 24 hours resulted in a significant increase in proliferation in response to LTD 4 . The enhanced proliferation was totally prevented by pretreating the cytokine-primed BSMC with the selective CysLT1 receptor antagonist Montelukast. Conclusions: Taken together, our findings indicate a synergy between certain cytokines and cysLTs, mediated by the augmented expression of the CysLT1 receptor and subsequent LTD 4 -triggered BSMC proliferation. These findings support a role for cysLTs in the airway remodeling observed in asthmatic patients and may provide a rationale for preventive and therapeutic intervention.

[1]  M. Millan,et al.  Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. , 2002, Molecular pharmacology.

[2]  R. Panettieri,et al.  IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[3]  S. Rennard,et al.  Interleukin-4- and interleukin-13-enhanced transforming growth factor-beta2 production in cultured human bronchial epithelial cells is attenuated by interferon-gamma. , 2002, American journal of respiratory cell and molecular biology.

[4]  C. Bonfanti,et al.  A Partially Humanized Monoclonal Antibody to Human IFN‐γ Inhibits Cytokine Effects both In Vitro and In Vivo , 2002, Scandinavian journal of immunology.

[5]  S. Johnston,et al.  Peripheral blood CD4+ and CD8+ T cell type 1 and type 2 cytokine production in atopic asthmatic and normal subjects , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  M. Ernst,et al.  Atopic Phenotype in Children Is Associated with Decreased Virus-Induced Interferon-α Release , 2002, International Archives of Allergy and Immunology.

[7]  E. Chi,et al.  A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. , 2002, American journal of respiratory and critical care medicine.

[8]  R. Panettieri,et al.  Interferon-gamma modulates cysteinyl leukotriene receptor-1 expression and function in human airway myocytes. , 2001, American journal of respiratory and critical care medicine.

[9]  N. Kaminski,et al.  Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. , 2001, American journal of respiratory cell and molecular biology.

[10]  R. Homer,et al.  Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β1 , 2001, The Journal of experimental medicine.

[11]  K. Tadokoro,et al.  In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma , 2001, British Journal of Cancer.

[12]  J. Stankova,et al.  IL-13 and IL-4 Up-Regulate Cysteinyl Leukotriene 1 Receptor Expression in Human Monocytes and Macrophages1 , 2001, The Journal of Immunology.

[13]  R. Djukanović,et al.  The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. , 2001, American journal of respiratory cell and molecular biology.

[14]  J. Renauld.  New insights into the role of cytokines in asthma , 2001, Journal of clinical pathology.

[15]  J. Kinet,et al.  Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. , 2001, American journal of respiratory and critical care medicine.

[16]  An Autosome‐Wide Search for Loci Underlying Wheezing Age of Onset in German Asthmatic Children Identifies a New Region of Interest on 6q24–q25 , 2001, Genetic epidemiology.

[17]  J. Stankova,et al.  IL-5 Up-Regulates Cysteinyl Leukotriene 1 Receptor Expression in HL-60 Cells Differentiated into Eosinophils1 , 2000, The Journal of Immunology.

[18]  Mary Jane Thomassen,et al.  Regulation of No Synthesis Transcriptional and Post-translational Oxide (no) in Asthma: Evidence for Molecular Mechanisms of Increased Nitric , 2013 .

[19]  P. Subramaniam,et al.  Inhibitory Effects of IFN-γ and Acyclovir on the Glioblastoma Cell Cycle , 2000 .

[20]  J. Elias,et al.  Airway remodeling in asthma. Unanswered questions. , 2000, American journal of respiratory and critical care medicine.

[21]  J. Rosenbloom,et al.  IGFBP-3 mediates TGF-beta1-induced cell growth in human airway smooth muscle cells. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[22]  S. Holgate,et al.  Antileukotriene therapy. Future directions. , 2000, American journal of respiratory and critical care medicine.

[23]  M. Hershenson,et al.  Mitogen-activated signaling and cell cycle regulation in airway smooth muscle. , 2000, Frontiers in bioscience : a journal and virtual library.

[24]  G. Verleden,et al.  Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines. , 1999, American journal of respiratory cell and molecular biology.

[25]  D. A. Walsh,et al.  Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats , 1999, British journal of pharmacology.

[26]  Jilly F. Evans,et al.  Characterization of the human cysteinyl leukotriene CysLT1 receptor , 1999, Nature.

[27]  R. Homer,et al.  Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. , 1999, The Journal of clinical investigation.

[28]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[29]  E. Chilvers,et al.  Platelet-derived growth factor-BB and thrombin activate phosphoinositide 3-kinase and protein kinase B: role in mediating airway smooth muscle proliferation. , 1998, Molecular pharmacology.

[30]  J. D. de Jongste,et al.  Angiotensin II induces hypertrophy of human airway smooth muscle cells: expression of transcription factors and transforming growth factor-beta1. , 1998, American journal of respiratory cell and molecular biology.

[31]  R. Panettieri,et al.  Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction In vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. , 1998, American journal of respiratory cell and molecular biology.

[32]  R. Martin,et al.  Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. , 1997, American journal of respiratory cell and molecular biology.

[33]  S. Durham,et al.  Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. , 1997, The Journal of allergy and clinical immunology.

[34]  J. Meléndez-Zajgla,et al.  Paclitaxel-induced apoptosis in HeLa cells is serum dependent. , 1996, Journal of biochemical toxicology.

[35]  G. Simonneau,et al.  Transforming growth factor beta in normal human lung: preferential location in bronchial epithelial cells. , 1994, Thorax.

[36]  B. Corrin,et al.  Immunohistochemical localization of transforming growth factor‐β1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders , 1994, Histopathology.

[37]  P. Paré,et al.  A model of airway narrowing in asthma and in chronic obstructive pulmonary disease. , 1992, The American review of respiratory disease.

[38]  P. Paré,et al.  The mechanics of airway narrowing in asthma. , 1989, The American review of respiratory disease.